Skip to main content

Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases

Immunology
0
Pipeline Programs
10
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.

$15.0B marketMature↑ Growing30 products15 companies

Key Trends

  • JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
  • Multiple patent cliffs emerging 2026-2028, creating generic competition risk
  • Robust pipeline with 4,996 trials signals continued innovation and market expansion

Career Verdict

Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1MOUNJAROGrowing
$2.4B
#2SYMBICORTStable
$2.0B
AstraZeneca·LOE_APPROACHING
#3JAKAFIDeclining
$1.9B
Incyte·LOE_APPROACHING2.6yr
#4RESTASISStable
$1.5B
AbbVie·PEAK8.0yr
#5RINVOQGrowing
$976M
AbbVie·PEAK11.8yr

Drug Class Breakdown

Janus Kinase Inhibitors
$3.0B(20%)

dominant class with patent cliff risk

Corticosteroid Hormone Receptor Agonists
$2.8B(19%)

established, mature market segment

G-Protein-linked Receptor Interactions
$2.4B(16%)

driven by single blockbuster

Calcineurin Inhibitors
$1.6B(11%)

established immunosuppression class

Tumor Necrosis Factor Receptor Blocking Activity
$1.2B(8%)

legacy biologic class with competition

Career Outlook

Growing

Immunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.

Breaking In

Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.

For Experienced Professionals

Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.

In-Demand Skills

Medical Affairs and MSL expertise in immunosuppression and inflammatory diseasesJAK inhibitor mechanism expertise and competitive positioningClinical trial design and phase transition managementCommercial acumen for premium-priced biologics and small moleculesRegulatory strategy for label expansions and lifecycle management

Best For

Medical Science LiaisonBrand ManagerSenior Medical Affairs ManagerClinical Development ManagerCommercial Strategy Lead

Hiring Landscape

$212K-$387K

Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.

340
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

45Growing
31Growing
29Stable

By Department

Medical Affairs(32%)
$257K
Commercial(24%)
$270K
Research & Development(9%)
$387K
Clinical Operations(4%)
$345K
Manufacturing(2%)
$212K

Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
1 program
The Mycophenolate Pregnancy RegistryN/A1 trial
Active Trials
NCT01733082Recruiting500Est. Dec 2040
Hetero
HeteroIndia - Hyderabad
1 program
The Mycophenolate Pregnancy RegistryN/A
Hikma
HikmaNJ - Berkeley Heights
1 program
The Mycophenolate Pregnancy RegistryN/A
Teva
TevaIsrael - Petach Tikva
1 program
The Mycophenolate Pregnancy RegistryN/A
Biocon
BioconIndia - Bangalore
1 program
The Mycophenolate Pregnancy RegistryN/A
Ascend Therapeutics
1 program
The Mycophenolate Pregnancy RegistryN/A
Accord Biopharma
Accord BiopharmaNC - Raleigh
1 program
The Mycophenolate Pregnancy RegistryN/A
Sandoz
SandozAustria - Kundl
1 program
The Mycophenolate Pregnancy RegistryN/A
Novartis
NovartisBASEL, Switzerland
1 program
The Mycophenolate Pregnancy RegistryN/A
Jubilant Therapeutics
1 program
The Mycophenolate Pregnancy RegistryN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GenentechThe Mycophenolate Pregnancy Registry

Clinical Trials (1)

Total enrollment: 500 patients across 1 trials

NCT01733082GenentechThe Mycophenolate Pregnancy Registry

The Mycophenolate Pregnancy Registry

Start: Nov 2012Est. completion: Dec 2040500 patients
N/ARecruiting

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 500 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.